Anna A. Chami
Tours, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Intrabody B1 targeting TDP-43 modulates neuroinflammatory and metabolic pathways in a preclinical ALS model.
Journal: Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics
Published: April 17, 2026
Virus-mediated delivery of single-chain antibody targeting TDP-43 protects against neuropathology, cognitive impairment and motor deficit caused by chronic cerebral hypoperfusion.
Journal: Experimental neurology
Published: October 11, 2024
N-Terminal Fragments of TDP-43-In Vitro Analysis and Implication in the Pathophysiology of Amyotrophic Lateral Sclerosis and Frontotemporal Lobar Degeneration.
Journal: Genes
Published: August 02, 2024
Emerging Trends in the Field of Inflammation and Proteinopathy in ALS/FTD Spectrum Disorder.
Journal: Biomedicines
Published: April 28, 2023
A novel mutation in the cleavage site N291 of TDP-43 protein in a familial case of amyotrophic lateral sclerosis.
Journal: Amyotrophic lateral sclerosis & frontotemporal degeneration
Published: April 18, 2020
The debated toxic role of aggregated TDP-43 in amyotrophic lateral sclerosis: a resolution in sight?
The debated toxic role of aggregated TDP-43 in amyotrophic lateral sclerosis: a resolution in sight?
Journal: Brain : a journal of neurology
Published: November 08, 2018
Causative Genes in Amyotrophic Lateral Sclerosis and Protein Degradation Pathways: a Link to Neurodegeneration.
Journal: Molecular neurobiology
Published: August 09, 2017
Showing 1-9 of 9
Last Updated: 09/26/2026